Skip to main content
Caplight Logo









Likang Life Sciences

Likang Life Sciences

Private
BeijingHealthcare & Life Scienceshttps://likanglife.com/

Last Round

Corporate Funding

Jun 26, 2026

Est. Valuation

$137.4M

Total Funding Raised

$27.42M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Likang Life Sciences is a biotechnology company that develops personalized immune cell therapies and mRNA-based tumor neoantigen vaccines for cancer treatment.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Clinical Trials, Medical AI

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

personalized cancer immunotherapycancer vaccineneoantigen vaccinecancer immunotherapyT-cell therapypersonalized medicineprecision medicinemRNA vaccinedendritic cell therapybioinformaticsTCR-Tneoantigen epitope analysissolid tumor treatmentAI-driven drug discoverybiotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Likang Life Sciences Comparables

Compare Likang Life Sciences with similar companies based on industry and business-model similarity.

Likang Life Sciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Siwei Biotechnology
86%
NeoCura Bio-Medical Technology Co., Ltd.
85%
Anda Biopharma
83%

Likang Life Sciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Corporate FundingJun 26, 2026
StrategicFeb 24, 2025
AngelSep 21, 2023

Likang Life Sciences Investors

Notable investors and investment history

Likang Life Sciences investors
InvestorRounds
Beijing E-Town International Investment & Development Co., Ltd.Strategic

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 26, 2026

    $16.1M raised in corporate funding.

  • Jan 21, 2026

    Monthly visitors increased 430% MoM, reaching 2.8K.

Likang Life Sciences Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Likang Life Sciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Likang Life Sciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersBeijing
Employee Range3
Year Founded2019
Last FundingJun 26, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?